<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-5 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-5</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-5</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy treatment duration for melanoma, including treatment protocols, patient response categories, outcomes by duration and response level, and comparisons between different treatment duration strategies.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>The type of study (e.g., 'randomized controlled trial', 'retrospective cohort', 'prospective observational', 'meta-analysis', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>anti_pd1_agent</strong></td>
                        <td>str</td>
                        <td>The specific anti-PD1 agent(s) used (e.g., 'pembrolizumab', 'nivolumab', 'cemiplimab', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_duration</strong></td>
                        <td>str</td>
                        <td>The duration of anti-PD1 treatment studied or used (e.g., '1 year', '2 years', 'until progression', 'fixed 6 months', etc.). Include all durations if multiple are compared.</td>
                    </tr>
                    <tr>
                        <td><strong>patient_cohort_size</strong></td>
                        <td>str</td>
                        <td>Number of patients in the study or cohort being analyzed</td>
                    </tr>
                    <tr>
                        <td><strong>melanoma_stage</strong></td>
                        <td>str</td>
                        <td>The stage(s) of melanoma in the patient cohort (e.g., 'stage III', 'stage IV', 'metastatic', 'advanced', 'unresectable', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>response_categories</strong></td>
                        <td>str</td>
                        <td>What response categories were used to classify patients? (e.g., 'complete response (CR)', 'partial response (PR)', 'stable disease (SD)', 'progressive disease (PD)', or other classification systems)</td>
                    </tr>
                    <tr>
                        <td><strong>response_assessment_method</strong></td>
                        <td>str</td>
                        <td>How was response assessed? (e.g., 'RECIST 1.1', 'iRECIST', 'clinical assessment', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_by_duration</strong></td>
                        <td>str</td>
                        <td>What were the key outcomes (overall survival, progression-free survival, response rates, etc.) for different treatment durations? Be specific with numerical results, timepoints, and statistical significance if available.</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_by_response_level</strong></td>
                        <td>str</td>
                        <td>What were the outcomes stratified by response level (e.g., outcomes for CR vs PR vs SD patients)? Include numerical results and comparisons if available.</td>
                    </tr>
                    <tr>
                        <td><strong>duration_by_response_findings</strong></td>
                        <td>str</td>
                        <td>Were there specific findings about whether optimal duration differs by response level? (e.g., 'CR patients had similar outcomes with 1 vs 2 years', 'PR patients benefited from extended treatment', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_discontinuation_reasons</strong></td>
                        <td>str</td>
                        <td>What were the reasons for treatment discontinuation? (e.g., 'completed planned duration', 'toxicity', 'progression', 'patient choice', etc.) Include percentages if available.</td>
                    </tr>
                    <tr>
                        <td><strong>discontinuation_timing</strong></td>
                        <td>str</td>
                        <td>At what timepoints was treatment commonly discontinued, and what were the outcomes? (e.g., 'median time to discontinuation', 'outcomes after early vs late discontinuation', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>relapse_after_discontinuation</strong></td>
                        <td>str</td>
                        <td>What were the relapse or progression rates after treatment discontinuation, and did this differ by duration or response level? Include specific rates and timeframes if available.</td>
                    </tr>
                    <tr>
                        <td><strong>adverse_events_by_duration</strong></td>
                        <td>str</td>
                        <td>Were there differences in adverse events or toxicity based on treatment duration? Include specific events and rates if available.</td>
                    </tr>
                    <tr>
                        <td><strong>comparison_between_durations</strong></td>
                        <td>str</td>
                        <td>If the study compared different treatment durations, what were the key comparative findings? (e.g., 'no significant difference in OS between 1 and 2 years', 'longer duration improved PFS', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>recommendations_on_duration</strong></td>
                        <td>str</td>
                        <td>What recommendations or conclusions did the authors make about optimal treatment duration? Include any response-dependent recommendations.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>